Drug Deal Disclosure Act

Summary#

This bill, the Drug Deal Disclosure Act, would require the Secretary of Health and Human Services (HHS) to publish, in a searchable and downloadable central place, records and communications about certain drug pricing agreements made on or after January 20, 2025. The covered records include contracts, meeting notes, memoranda, directives, logs, metadata, and related materials when agreements include provisions such as references to prices in other countries, direct-to-consumer discounts, import or duty exemptions, investment or repatriation commitments, special treatment in Medicare demonstration projects (including GLOBE and GUARD), contributions to the Strategic National Stockpile, or receipt of certain FDA priority review vouchers. The bill lists specific manufacturer agreements to be disclosed and requires HHS to disclose future qualifying agreements within 30 days of ratification.

The bill bars withholding records for reasons of reputational harm or political sensitivity. HHS may withhold or redact proprietary pricing information or material legally prohibited from disclosure, but must state whether it received confidential pricing information from each manufacturer and must publish a written justification for any redaction in the Federal Register and submit it to Congress.

The bill also requires HHS to report to several congressional committees within 15 days after the release is complete about what was released and withheld, and it directs the Congressional Budget Office and the Government Accountability Office to publish a joint report on economic and budgetary effects within 90 days after release.

What it means for you#

• The public, journalists, researchers, and health care stakeholders would be able to access many government and interagency records about specified drug pricing agreements.
• Some pricing details may be redacted if marked proprietary or barred from disclosure by foreign law or court orders; HHS must explain any redactions.
• The bill does not itself change how drugs are priced or paid for; it focuses on release of documents and follow-up analysis by federal agencies.

Expenses#

No publicly available information on direct federal costs or savings is included in the bill text. The bill requires HHS to publish records and to report to Congress, and it directs the CBO and GAO to produce an analysis of economic and budgetary effects, but it does not include dollar estimates or specific budget authority in the text provided.

Proponents' View#

No publicly available information in the bill text or metadata states proponents' arguments or claims.

Opponents' View#

No publicly available information in the bill text or metadata states opponents' arguments or claims.